APR 15, 2021 9:20 AM PDT

Magic Mushroom Therapy and Antidepressants Produce Similar Results

WRITTEN BY: Annie Lennon

In recent years, psilocybin (the psychoactive ingredient in 'magic mushrooms') has gained increasing amounts of media attention following clinical trials demonstrating its ability to treat depression. Now, a new study by Imperial College London has found that, over a six-week period, psilocybin has similar effects on depression to antidepressant escitalopram. 

For the study, the researchers enrolled 59 patients suffering from long-standing, moderate-to-severe major depressive disorder. One group of 30 participants were assigned to receive two doses of 25mg of psilocybin three weeks apart alongside six weeks of a daily placebo. Meanwhile, another group of 29 participants received two doses of 1 mg psilocybin three weeks apart alongside six weeks of daily oral escitalopram, a selective serotonin reuptake inhibitor (SSRI). 

The researchers assessed how these treatments, conducted over a 6-week period, affected patients' scores for depression on the 16-item Quick Inventory for Depressive Symptomatology-Self Report. The inventory scores patients from 0 to 27, 27 indicating more severe depression and remission characterized by a score lower than 5. 

All in all, the trial did not show a significant difference in depression scores between those on psilocybin and those on escitalopram. Those in the psilocybin group had a mean difference in score or -8 compared to -6 for those treated with escitalopram. Although secondary outcomes (reduction in score of over 50%) were generally more common in the psilocybin group, analyses of these outcomes lacked correction for multiple comparisons and thus should not be over-interpreted. 

The researchers nevertheless say that these results signal hope for the potential of psilocybin-assisted psychotherapy to treat depression. To understand how the treatment may give maximum benefit to patients, however, and how it differs from more conventional treatments, larger and longer trials are required. 

 

Sources: The New England Journal of MedicineThe Guardian

About the Author
Other
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
DEC 05, 2022
Drug Discovery & Development
Characterization and Manufacturing of AAVs for Gene Therapy
Characterization and Manufacturing of AAVs for Gene Therapy
The backdrop upon which every successful gene therapy is developed is the ability to safely and specifically target cell ...
DEC 02, 2022
Neuroscience
Scientists Identify Distinct Brain Networks Associated with Risk and Resilience in Depression
Scientists Identify Distinct Brain Networks Associated with Risk and Resilience in Depression
A study published in Brain found a link between the location of brain injury to levels of depression in patients followi ...
DEC 12, 2022
Clinical & Molecular DX
NIH Awards Millions of Dollars to Develop a Drug to Target the Emerging Chikungunya Virus
NIH Awards Millions of Dollars to Develop a Drug to Target the Emerging Chikungunya Virus
Chikungunya virus is a mosquito-borne illness, meaning it is spread by the bite of an infected mosquito. The virus can c ...
DEC 17, 2022
Health & Medicine
A Universal Antidote for Drug Overdoses is in Development
A Universal Antidote for Drug Overdoses is in Development
Drug overdose deaths continue to rise in the United States. About 92,000 people died from drug and prescription opi ...
DEC 19, 2022
Cancer
TIL Therapy for Advanced Melanoma Extends Survival Over Ipilimumab
TIL Therapy for Advanced Melanoma Extends Survival Over Ipilimumab
Immune checkpoint inhibitors (ICIs) have become a treatment option for many patients with advanced melanoma.  Still ...
JAN 19, 2023
Drug Discovery & Development
Newest Treatment for Rosacea: Encapsulated Benzoyl Peroxide Cream
Newest Treatment for Rosacea: Encapsulated Benzoyl Peroxide Cream
Rosacea is a dermatologic condition affecting the centrofacial region (cheeks, chin, nose, and forehead), resulting ...
Loading Comments...